Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

• Published in: Neurology Vol. 50; no. 3; p. 669
• Main Authors: Farlow, M R, Lahiri, D K, Poirier, J, Davignon, J, Schneider, L, Hui, S L
• Format: Journal Article
• Language: English
• Published: United States 01.03.1998
• Subjects: Aged; Alzheimer Disease - blood; Alzheimer Disease - drug therapy; Alzheimer Disease - psychology; Apolipoprotein E4; Apolipoproteins - blood; Apolipoproteins - genetics; Apolipoproteins E - analysis; Cholinesterase Inhibitors - therapeutic use; Cognition - physiology; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Sex Characteristics; Tacrine - therapeutic use; Treatment Outcome
• ISSN: 0028-3878
• DOI: 10.1212/WNL.50.3.669

We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double-blind, placebo-controlled trial of tacrine, in which APOE genotypes were...